Research programme: cancer vaccine - Inovio Pharmaceuticals/MedImmune

Drug Profile

Research programme: cancer vaccine - Inovio Pharmaceuticals/MedImmune

Latest Information Update: 24 Aug 2015

Price : $50

At a glance

  • Originator Inovio Pharmaceuticals
  • Developer Inovio Pharmaceuticals; MedImmune
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 10 Aug 2015 Early research in Cancer in USA (unspecified route)
  • 10 Aug 2015 MedImmune enters into collaboration with Inovio Pharmaceuticals for the development and commercialisation of vaccines for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top